Beside monoclonal antibodies a recombinant FH derived protein composed of CCPs 18-20 (hSCR18-20) was successfully used to inhibit the binding of FH to chronic lymphocytic leukemia cells and an FHR-4—anti-HER2 immunoconjugate was able to induce complement dependent cytotoxicity on HER2 expressing tumor cells that are known to be resistant to complement mediated lysis (159–161). This evidence concerns the gene FH and neoplasm.